SLC5A2 and peripheral arterial disease: Recent studies have also revealed that another FDA-approved anti-diabetic class of drugs, gliflozins, which lower blood glucose by suppressing kidney glucose reabsorption by inhibiting sodium-glucose cotransporter 2 (SGLT2) 189, are also potential small molecule drug candidate for treating PAD.